26,828 Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Acquired by Point72 Asset Management L.P.

Point72 Asset Management L.P. purchased a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 26,828 shares of the specialty pharmaceutical company's stock, valued at approximately $970,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in Supernus Pharmaceuticals by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 6,150,759 shares of the specialty pharmaceutical company's stock worth $222,411,000 after purchasing an additional 22,852 shares during the last quarter. Geode Capital Management LLC lifted its stake in Supernus Pharmaceuticals by 1.9% in the fourth quarter. Geode Capital Management LLC now owns 1,510,568 shares of the specialty pharmaceutical company's stock worth $54,633,000 after purchasing an additional 28,517 shares during the last quarter. American Century Companies Inc. lifted its stake in Supernus Pharmaceuticals by 9.2% in the fourth quarter. American Century Companies Inc. now owns 1,140,705 shares of the specialty pharmaceutical company's stock worth $41,248,000 after purchasing an additional 95,777 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Supernus Pharmaceuticals by 5.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 753,363 shares of the specialty pharmaceutical company's stock worth $27,242,000 after purchasing an additional 40,968 shares during the last quarter. Finally, Northern Trust Corp lifted its stake in Supernus Pharmaceuticals by 18.3% in the fourth quarter. Northern Trust Corp now owns 717,161 shares of the specialty pharmaceutical company's stock worth $25,933,000 after purchasing an additional 110,867 shares during the last quarter.

Analyst Upgrades and Downgrades

SUPN has been the subject of several analyst reports. Wall Street Zen raised shares of Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, May 16th. Cantor Fitzgerald reissued a "neutral" rating and issued a $36.00 price objective on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th.

Supernus Pharmaceuticals Trading Up 1.4%

Shares of Supernus Pharmaceuticals stock traded up $0.44 on Tuesday, hitting $32.54. 30,664 shares of the company traded hands, compared to its average volume of 481,929. The stock's 50 day moving average price is $31.98 and its 200-day moving average price is $34.70. Supernus Pharmaceuticals, Inc. has a 52 week low of $25.53 and a 52 week high of $40.28. The company has a market cap of $1.82 billion, a PE ratio of 30.36 and a beta of 0.74.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.